Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Merkel Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

pembrolizumab 15avelumab 12Nivolumab 9atezolizumab 5Cyclophosphamide 5fludarabine 4Interleukin-2 4ALT-803 4durvalumab 3cemiplimab 3aldesleukin 3Ipilimumab 3domatinostat 2budigalimab 2Paclitaxel 2Docetaxel 2Bevacizumab 2zimberelimab 1venetoclax 1talimogene laherparepvec 1rovalpituzumab tesirine 1regorafenib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lorvotuzumab mertansine 1glucopyranosyl lipid-A 1epacadostat 1efineptakin alfa 1daromun 1bempegaldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Merkel Cell × domatinostat × Clear all
NCT04393753 2024-05-08

MERKLIN2

4SC AG

Phase 2 Completed
19 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT04874831 2021-11-18

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

4SC AG

Phase 2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡